Intragastric Balloon Market — By Product, By Filling Material, By Administration, By End Use, Global Forecast, 2025 to 2034

Intragastric Balloon Market Size

The global intragastric balloon market size was valued at USD 68.5 million in 2024 and is expected to exhibit growth at a CAGR of 14.8% from 2025 to 2034. The high market growth can be attributed to technological advancements and improved devices, growing awareness of obesity-related diseases, and increased availability of medical support and insurance coverage, among other contributing factors.
 

Moreover, the increasing prevalence of obesity worldwide is creating a higher demand for weight-loss solutions. For instance, according to the World Health Organization (WHO) data from 2023, more than 1 billion people globally are obese, including 160 million children. The Centers for Disease Control and Prevention (CDC) reported in 2022 that 42.4% of U.S. adults were obese, with an estimated annual medical cost of USD 173 billion. These rising obesity rates are prompting individuals to pursue treatments like intragastric balloons to control their weight and minimize health risks associated with obesity, including diabetes and cardiovascular disease.
 

Intragastric balloon is a non-surgical weight-loss device placed in the stomach to reduce its capacity, helping patients feel fuller with less food. It is typically used for obese individuals who have not been successful with diet and exercise alone. The balloon is inserted via endoscopy or a pill and removed after a few months.
 

Intragastric Balloon Market Trends

The market is witnessing significant growth driven by continuous innovations in balloon technology, increasing demand for non-invasive weight loss solutions, and expansion of clinical applications, among other factors are boosting the industry growth.
 

• Further, there is a growing demand for personalized medicine in weight management. Healthcare providers are customizing intragastric balloon treatment plans based on individual factors such as age, gender, BMI, and coexisting health conditions. This personalized approach enhances patient outcomes and drives adoption.
   
• Additionally, public health initiatives aimed at reducing obesity rates are gaining momentum, increasing awareness of non-surgical weight loss options like intragastric balloons. These campaigns educate the public about the health risks of obesity and promote available treatments, contributing to the growing market demand.
   

Intragastric Balloon Market Analysis

Based on product, the market is classified into single intragastric balloon, dual intragastric balloon, and triple intragastric balloon. The single intragastric balloon segment generated the highest revenue of USD 41.2 million in 2024.
 

• Single intragastric balloons are simpler to deploy compared to dual-balloon devices. They involve a straightforward insertion process and can be placed more quickly, which is appealing to both healthcare providers and patients. This simplicity reduces procedure time and minimizes the likelihood of complications, contributing to their widespread use.
   
• Furthermore, these balloons are generally less expensive than dual-balloon systems. This makes them an attractive option for patients who may be seeking a more affordable weight-loss solution. Additionally, their lower cost allows for greater market accessibility, particularly in regions with price-sensitive populations or limited insurance coverage for such treatments.
   

Based on filling material, the intragastric balloon market is classified into saline-filled balloon and gas-filled balloon. The saline-filled balloon segment accounted for USD 48.2 million in market revenue in 2024 and is anticipated to grow at a CAGR of 14.5% between 2025 to 2034 period.
 

• Saline-filled balloons are known for their strong safety profile. The saline solution inside the balloon ensures that if the balloon leaks or bursts, it causes minimal harm, as the body can absorb the saline without significant adverse effects. This safety feature makes saline-filled balloons an appealing option for patients and healthcare providers concerned about complications.
   
• Additionally, it offers a more controlled and stable inflation process compared to air-filled balloons, which are more prone to deflation or leakage. This reduces the risk of balloon-related issues and enhances the long-term effectiveness of the treatment, making it a reliable choice for weight loss. These advantages are expected to drive growth in this segment of the market.
   

Based on administration, the intragastric balloon market is classified into endoscopy and pill form. The endoscopy segment dominated the market in 2024 with a market share of 74.3%.
 

• Endoscopy is a minimally invasive technique, which significantly reduces the risks associated with traditional surgery. It involves inserting the balloon into the stomach through the mouth using an endoscope, without the need for incisions or stitches. This makes it a highly appealing option for patients seeking less invasive alternatives to weight loss surgery, driving its adoption in the market.
   
• Further, the endoscopic procedure for inserting the intragastric balloon typically requires only local anesthesia or mild sedation, rather than general anesthesia. This results in reduced discomfort and faster recovery for patients. The less invasive nature of endoscopy enhances patient satisfaction and increases the likelihood of adoption.
   

Based on end use, the intragastric balloon market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 112.4 million by the end of the forecast period.
 

• The increasing global obesity rates have prompted hospitals to provide effective weight management solutions. Intragastric balloon treatments offer a non-surgical approach to address obesity and related health conditions, including diabetes and heart disease. This has led hospitals to incorporate these treatments into their medical services.
   
• Moreover, offering intragastric balloon treatments provides hospitals with a new revenue stream. As demand for weight-loss treatments rises, hospitals can capitalize on this trend by incorporating the procedure into their service offerings. Additionally, it provides hospitals with the opportunity to enhance their bariatric services without the need for complex surgical infrastructure.
   

U.S. intragastric balloon market accounted for USD 24.9 million market revenue in 2024 and is anticipated to grow at a CAGR of 14.8% between 2025 to 2034 period.
 

• The approval of intragastric balloons by the U.S. Food and Drug Administration (FDA) has enhanced their credibility and market acceptance. FDA clearance provides patients and healthcare providers with confidence in the safety and effectiveness of the devices, driving their adoption across the U.S. healthcare system.
   
• Additionally, the U.S. healthcare consumers are increasingly seeking out minimally invasive treatments, driven by the desire for reduced recovery times, lower complication rates, and quicker return to normal activities. The non-surgical nature of intragastric balloon procedures fits well with this trend, making them an attractive weight-loss solution for patients and contributing to market growth.
   

Germany intragastric balloon market is projected to grow remarkably in the coming years.
 

• Germany has a strong culture of adopting innovative medical technologies, and minimally invasive procedures are becoming increasingly popular. The growing acceptance of endoscopic procedures for intragastric balloon placement aligns with the broader trend of patients seeking non-invasive options that offer reduced recovery time and fewer complications.
   
• Positive clinical outcomes, including significant weight loss and improved health metrics, have led to higher patient satisfaction. As more patients achieve successful results, word-of-mouth and positive testimonials further boost the adoption of intragastric balloons in Germany.
   

Japan holds a dominant position in the Asia Pacific intragastric balloon market.
 

• Japan's aging population, with 29.1% of individuals over 65 years old in 2023 according to the Ministry of Internal Affairs and Communications, faces increased health risks related to obesity.
   
• The National Health and Nutrition Survey 2022 reported that 32.4% of Japanese adults aged 65-74 were overweight, driving the demand for non-surgical weight-loss treatments such as intragastric balloons. These treatments offer an alternative to bariatric surgery, particularly benefiting elderly patients who may not be suitable candidates for invasive procedures.
   

Intragastric Balloon Market Share

The market is characterized by the presence of several key players, including Boston Scientific (Apollo Endosurgery), OBALON, and Allurion. These companies compete by offering innovative, FDA-approved balloon devices that cater to different patient needs, such as enhanced comfort, safety, and ease of use. Key competitive factors include technological advancements, regulatory approvals, pricing strategies, and market penetration, with companies focusing on expanding their global reach and improving patient outcomes to gain a competitive edge.
 

Intragastric Balloon Market Companies

Prominent players operating in the intragastric balloon industry include:

• Allurion
• Boston Scientific (Apollo Endosurgery)
• districlass medical
• endalis
• HEALTH WARE
• helioscopie
• Medicone
• medispar
• OBALON
• ReShape Lifesciences
• SHENYUN
• SILIMED
• SPATZ
   

Intragastric Balloon Industry News:

• In October 2024, Allurion Technologies, Inc. announced the submission of the first three modules of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The company anticipated filing the fourth and final module, which contains clinical data from its AUDACITY trial, early the following year. This move positions Allurion to receive FDA approval, enabling the company to expand its market presence and enhance credibility in the weight-loss solutions sector.
   
• In February 2024, Spatz Medical announced the commercialization of the Spatz3 adjustable gastric balloon. With over 150,000 patients benefiting from the Spatz3 across more than sixty markets globally, the company launched this revolutionary technology in the U.S. This move allows the company to expand its market reach and strengthen its position as a key player in the weight loss solutions sector.
   

The intragastric balloon market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Single intragastric balloon
• Dual intragastric balloon
• Triple intragastric balloon

Market, By Filling Material

• Saline-filled balloon
• Gas-filled balloon

Market, By Administration

• Endoscopy
• Pill form

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE